Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5409 |
Name | lung small cell carcinoma |
Definition | A lung carcinoma that has_material_basis_in primitive-appearing cells that are smaller than normal cells and is located_in the lung. |
Source | DiseaseOntology.org |
Alt Ids | DOID:0050875 |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung small cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 inact mut | APR-246 | lung small cell carcinoma | sensitive | detail... |
RET wild-type | Vandetanib | lung small cell carcinoma | sensitive | detail... |
RET M918T | Ponatinib | lung small cell carcinoma | sensitive | detail... |
RET wild-type | Ponatinib | lung small cell carcinoma | sensitive | detail... |
RET M918T | Vandetanib | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | Zoligratinib | lung small cell carcinoma | sensitive | detail... |
TP53 Y163C | APR-246 + Cisplatin | lung small cell carcinoma | sensitive | detail... |
RB1 loss | Trilaciclib | lung small cell carcinoma | resistant | detail... |
RB1 loss | Topotecan + Trilaciclib | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | Fexagratinib | lung small cell carcinoma | sensitive | detail... |
PIK3CA act mut | Navitoclax + Pictilisib | lung small cell carcinoma | predicted - sensitive | detail... |
TP53 S241F | APR-246 | lung small cell carcinoma | sensitive | detail... |
TP53 R273L | APR-246 | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | RO4987655 | lung small cell carcinoma | no benefit | detail... |
FGFR1 amp | RO5126766 | lung small cell carcinoma | no benefit | detail... |
FGFR1 amp | Selumetinib | lung small cell carcinoma | no benefit | detail... |
FGFR1 rearrange | Fexagratinib | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | E7090 | lung small cell carcinoma | sensitive | detail... |
ALK rearrange RB1 C706F TP53 loss | Lorlatinib | lung small cell carcinoma | predicted - resistant | detail... |
FGFR1 amp | Buparlisib + Fexagratinib | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | GSK3052230 | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | Cisplatin + Etoposide + GSK3052230 | lung small cell carcinoma | sensitive | detail... |
CHEK1 over exp | PF-00477736 | lung small cell carcinoma | sensitive | detail... |
CHEK1 over exp | Berzosertib | lung small cell carcinoma | sensitive | detail... |
ATM D2725G | Temozolomide + Veliparib | lung small cell carcinoma | predicted - sensitive | detail... |
ATM S333F | Temozolomide + Veliparib | lung small cell carcinoma | predicted - sensitive | detail... |
ATM V410A | Temozolomide + Veliparib | lung small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange | Alectinib + Irinotecan | lung small cell carcinoma | predicted - sensitive | detail... |
TP53 Y220C | PC14586 | lung small cell carcinoma | predicted - sensitive | detail... |
RET C620Y | Selpercatinib | lung small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK V1180L | Lorlatinib | lung small cell carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00926640 | Phase I | Belinostat + Cisplatin + Etoposide | A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | Completed | USA | 0 |
NCT01286987 | Phase I | Talazoparib | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | Completed | USA | GBR | 0 |
NCT01306045 | Phase II | Erlotinib Lapatinib MK2206 Sunitinib Selumetinib | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | Completed | USA | 0 |
NCT01450761 | Phase III | Cisplatin Ipilimumab Carboplatin Etoposide | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | Completed | USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 13 |
NCT01579929 | Phase I | Cisplatin + Etoposide + Sonidegib | Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Completed | USA | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | NLD | GBR | FRA | ESP | AUS | 1 |
NCT01638546 | Phase II | Temozolomide Veliparib | Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | Completed | USA | 0 |
NCT01642251 | Phase Ib/II | Cisplatin + Etoposide Veliparib | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01722292 | Phase Ib/II | Taladegib Carboplatin + Etoposide | A Study of LY2940680 in Small Cell Lung Cancer | Terminated | USA | GBR | 0 |
NCT01737502 | Phase Ib/II | Auranofin + Sirolimus | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | Completed | USA | 0 |
NCT01831089 | Phase I | Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Completed | USA | ESP | CHE | 0 |
NCT01859741 | Phase Ib/II | Cisplatin Etoposide Carboplatin Tarextumab | A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE) | Terminated | USA | 0 |
NCT01892046 | Phase I | Carboplatin SNX-5422 Paclitaxel | Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors | Completed | USA | 0 |
NCT01928394 | Phase Ib/II | Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ITA | GBR | FIN | ESP | DNK | DEU | CAN | 0 |
NCT02034123 | Phase I | GSK2879552 | Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma | Terminated | USA | FRA | ESP | 0 |
NCT02038647 | Phase II | Paclitaxel Alisertib | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | Completed | USA | POL | ITA | HUN | FRA | ESP | DEU | CZE | CAN | BEL | 0 |
NCT02100007 | Phase Ib/II | ME-344 + Topotecan | ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors | Terminated | USA | GBR | 0 |
NCT02152059 | Phase II | Nintedanib | A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy | Withdrawn | CAN | 0 |
NCT02157792 | Phase I | Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine | M6620 First in Human Study | Completed | USA | GBR | 0 |
NCT02161419 | Phase II | Roniciclib | RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer | Terminated | USA | POL | ITA | HUN | FRA | DEU | BEL | 2 |
NCT02200757 | Phase II | Aldoxorubicin Topotecan | Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | Completed | USA | HUN | ESP | 0 |
NCT02247349 | Phase Ib/II | BMS-986012 BMS-986012 + Nivolumab | BMS-986012 in Relapsed/Refractory SCLC | Completed | USA | NLD | CAN | BEL | AUS | 2 |
NCT02250885 | Phase II | Selinexor | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | Completed | USA | 0 |
NCT02261805 | Phase Ib/II | Aldoxorubicin + Ganetespib | A Phase I/II Study of Ganetespib in Combination With Doxorubicin | Terminated | USA | 0 |
NCT02289690 | Phase I | Carboplatin + Etoposide + Veliparib | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | Completed | USA | ROU | NLD | HUN | FRA | ESP | CZE | CAN | BEL | AUS | 2 |
NCT02331251 | Phase Ib/II | Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Terminated | USA | 0 |
NCT02351505 | Phase II | Selinexor | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02359019 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy | Completed | USA | 0 |
NCT02402920 | Phase I | Carboplatin + Etoposide + Pembrolizumab Cisplatin | Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02419417 | Phase Ib/II | BMS986158 Paclitaxel | Study of BMS-986158 in Subjects With Select Advanced Solid Tumors | Completed | USA | FRA | ESP | CAN | AUS | 0 |
NCT02446704 | Phase Ib/II | Olaparib Temozolomide | Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | Unknown status | USA | 0 |
NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Completed | USA | SWE | ITA | GBR | FRA | ESP | DEU | CHE | BEL | 0 |
NCT02472977 | Phase Ib/II | Nivolumab Ulocuplumab | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors | Terminated | USA | FIN | 0 |
NCT02481830 | Phase III | Amrubicin Nivolumab Topotecan | Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer | Completed | USA | ROU | POL | NOR | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | BRA | BEL | AUT | AUS | 6 |
NCT02487095 | Phase Ib/II | Berzosertib Topotecan | Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02489903 | Phase II | Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel | RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens | Completed | USA | 0 |
NCT02498613 | Phase II | Cediranib + Olaparib | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02499770 | Phase Ib/II | Carboplatin + Etoposide Trilaciclib | G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | Completed | USA | POL | HUN | FRA | ESP | 2 |
NCT02514447 | Phase Ib/II | Trilaciclib Topotecan | Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | Terminated | USA | SVN | SVK | HRV | BEL | 3 |
NCT02516553 | Phase I | BI 894999 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | Completed | USA | FRA | ESP | DEU | BEL | 1 |
NCT02537418 | Phase I | Cisplatin + Etoposide Durvalumab Tremelimumab | Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens | Active, not recruiting | CAN | 0 |
NCT02538666 | Phase III | Ipilimumab Nivolumab | A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451) | Completed | USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
NCT02561234 | Phase I | Pegzilarginase | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02579226 | Phase I | Irinotecan AZD2811 | A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Recruiting | USA | POL | NOR | NLD | ITA | ISR | FRA | ESP | DNK | DEU | BRA | AUS | 9 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02649673 | Phase Ib/II | LCL161 + Topotecan | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | Terminated | USA | 0 |
NCT02658214 | Phase I | Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | Completed | 2 | |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | NZL | GBR | FRA | ESP | AUS | 0 |
NCT02671955 | Phase I | Onvatilimab | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated | USA | 0 |
NCT02674568 | Phase II | Rovalpituzumab Tesirine | Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY) | Completed | 0 | |
NCT02701400 | Phase II | Tavolimab + Tremelimumab | Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer | Completed | USA | 0 |
NCT02734004 | Phase Ib/II | Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) | Active, not recruiting | USA | NLD | ISR | GBR | FRA | CHE | 1 |
NCT02735980 | Phase II | Prexasertib | A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer | Completed | USA | TUR | NLD | GRC | GBR | FRA | ESP | DEU | 2 |
NCT02748889 | Phase Ib/II | Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide | Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02763579 | Phase III | Atezolizumab + Carboplatin + Etoposide Carboplatin + Etoposide | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133) | Completed | USA | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | BRA | AUT | AUS | 8 |
NCT02815592 | Phase Ib/II | Etoposide BMS-986012 + Cisplatin + Etoposide BMS-986012 + Carboplatin + Etoposide | Trial of BMS-986012 in Combination With Platinum and Etoposide | Completed | ESP | 0 |
NCT02819999 | Phase I | Cisplatin + Etoposide + Rovalpituzumab Tesirine Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02874664 | Phase I | Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer | Completed | USA | CAN | 0 |
NCT02875223 | Phase I | CC-90011 | A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | Terminated | ITA | GBR | FRA | ESP | 1 |
NCT02899728 | Phase II | Carboplatin + Cisplatin + Etoposide Cediranib + Olaparib | Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02922764 | Phase I | RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma | Active, not recruiting | USA | 0 |
NCT02934503 | Phase II | Carboplatin + Cisplatin + Etoposide + Pembrolizumab | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) | Terminated | USA | 0 |
NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Completed | USA | GBR | 0 |
NCT02963090 | Phase II | Pembrolizumab + Topotecan Pembrolizumab | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | Terminated | USA | 0 |
NCT03026166 | Phase I | Ipilimumab + Nivolumab + Rovalpituzumab Tesirine Nivolumab + Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | Terminated | USA | ITA | FRA | ESP | DEU | 0 |
NCT03033511 | Phase III | Dexamethasone + Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU) | Terminated | USA | TUR | SWE | POL | NOR | NLD | LVA | LTU | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | EST | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | 12 |
NCT03041311 | Phase II | Atezolizumab + Carboplatin + Etoposide + Trilaciclib Atezolizumab + Carboplatin + Etoposide | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC) | Terminated | USA | LVA | FRA | EST | ESP | BGR | 1 |
NCT03043599 | Phase Ib/II | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | Completed | USA | 0 |
NCT03043872 | Phase III | Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Etoposide Carboplatin + Cisplatin + Etoposide | Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian) | Active, not recruiting | USA | TUR | SVK | ROU | POL | NLD | ITA | ISR | HUN | FRA | ESP | DEU | CZE | BRA | BGR | AUT | ARG | 6 |
NCT03061812 | Phase III | Rovalpituzumab Tesirine Topotecan | Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE) | Completed | USA | TUR | SWE | ROU | POL | NLD | LVA | ITA | HUN | HRV | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | 11 |
NCT03066778 | Phase III | Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | Completed | USA | TUR | POL | NZL | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CHE | CAN | AUS | 5 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03080311 | Phase I | APG-1252 | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors | Completed | USA | 0 |
NCT03083691 | Phase II | Ipilimumab + Nivolumab | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | Completed | DEU | 0 |
NCT03085849 | Phase I | Durvalumab + Guadecitabine + Tremelimumab | SGI-110 Plus Durvalumab/Tremelimumab in SCLC | Completed | USA | 0 |
NCT03092934 | Phase Ib/II | LY3295668 | A Study of AK-01 (LY3295668) in Solid Tumors | Completed | CAN | 0 |
NCT03116971 | Phase Ib/II | Cisplatin + Etoposide + Peposertib Peposertib | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) | Terminated | USA | ROU | POL | ITA | HUN | GBR | ESP | DNK | DEU | CZE | CAN | BGR | BEL | 0 |
NCT03150810 | Phase Ib/II | Pamiparib + Temozolomide | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | AUS | 0 |
NCT03179436 | Phase Ib/II | MK-1308 + Pembrolizumab MK-1308 | Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | Completed | USA | SWE | POL | NZL | ITA | ISR | GRC | FRA | ESP | CAN | AUS | 5 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03221400 | Phase Ib/II | STA-8666 | PEN-866 in Patients With Advanced Solid Malignancies | Unknown status | USA | 0 |
NCT03227016 | Phase I | Topotecan + Veliparib | Study in Patients With SCLC of Veliparib in Combination With Topotecan | Unknown status | DEU | 0 |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) | Recruiting | USA | GBR | AUS | 1 |
NCT03319940 | Phase I | Tarlatamab | Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer | Active, not recruiting | USA | POL | NLD | GBR | FRA | ESP | DEU | CHE | AUT | AUS | 3 |
NCT03325816 | Phase Ib/II | Nivolumab | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | Completed | USA | 0 |
NCT03334487 | Phase III | Dexamethasone + Rovalpituzumab Tesirine | Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer | Withdrawn | USA | SWE | GBR | DEU | CAN | BRA | AUS | 0 |
NCT03361228 | Phase Ib/II | Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03363893 | Phase Ib/II | Samuraciclib Fulvestrant + Samuraciclib | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | Completed | USA | GBR | 0 |
NCT03365791 | Phase II | Ieramilimab Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03366103 | Phase Ib/II | Navitoclax + Vistusertib | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | Terminated | USA | 0 |
NCT03371979 | Phase Ib/II | Pegzilarginase + Pembrolizumab | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | Completed | USA | 1 |
NCT03382561 | Phase II | Cisplatin + Etoposide + Nivolumab Carboplatin + Etoposide + Nivolumab Cisplatin + Etoposide Carboplatin + Etoposide | Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer | Active, not recruiting | USA | 0 |
NCT03402880 | Phase II | Epacadostat + Pembrolizumab | ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT03406715 | Phase II | Ad.p53-DC vaccine + Ipilimumab + Nivolumab | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) | Terminated | USA | 0 |
NCT03460977 | Phase I | PF-06821497 | PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Recruiting | USA | POL | ESP | BGR | 4 |
NCT03467360 | Phase I | Atezolizumab | Inhibition of CArbonic Anhydrase in Combination With Platinum and Etoposide-based Radiochemotherapy in Patients With Localized Small Cell Lung Cancer (ICAR) | Recruiting | FRA | 0 |
NCT03509012 | Phase I | Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) | Active, not recruiting | USA | ESP | 3 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03532880 | Phase I | Olaparib | A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03554473 | Phase Ib/II | Bintrafusp alfa + Topotecan Bintrafusp alfa + Temozolomide Bintrafusp alfa | M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers | Recruiting | USA | 0 |
NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Completed | USA | 0 |
NCT03575793 | Phase Ib/II | Ipilimumab + Nivolumab + Plinabulin Ipilimumab + Nivolumab | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | Completed | USA | 0 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Completed | USA | 0 |
NCT03595059 | Phase I | Docetaxel + Mirzotamab clezutoclax Mirzotamab clezutoclax + Paclitaxel Mirzotamab clezutoclax | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | Active, not recruiting | USA | NLD | ISR | ESP | CAN | AUS | 4 |
NCT03639194 | Phase I | ABBV-011 + Budigalimab ABBV-011 | A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Completed | USA | 3 |
NCT03662074 | Phase II | Gemcitabine + Nivolumab | Second Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer | Terminated | USA | 0 |
NCT03670056 | Phase II | Ipilimumab + Nivolumab | A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy | Active, not recruiting | USA | 0 |
NCT03672773 | Phase II | Talazoparib + Temozolomide | Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Active, not recruiting | USA | 0 |
NCT03703297 | Phase III | Durvalumab Durvalumab + Tremelimumab | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) | Active, not recruiting | USA | TUR | POL | NLD | ITA | GBR | ESP | DEU | CZE | CAN | BEL | ARG | 7 |
NCT03708328 | Phase I | RO7121661 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Completed | USA | NZL | FRA | ESP | DNK | 1 |
NCT03728361 | Phase II | Nivolumab + Temozolomide | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer | Active, not recruiting | USA | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Active, not recruiting | USA | 0 |
NCT03811002 | Phase II | Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide | Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer | Active, not recruiting | USA | 1 |
NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | CAN | 0 |
NCT03830918 | Phase Ib/II | Niraparib + Temozolomide | Niraparib and Temozolomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | Recruiting | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT03850067 | Phase Ib/II | Carboplatin + CC-90011 + Etoposide CC-90011 + Cisplatin + Etoposide Nivolumab | A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer | Completed | ITA | FRA | ESP | 0 |
NCT03879798 | Phase Ib/II | DS-3201b + Irinotecan | DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer | Terminated | USA | 0 |
NCT03896503 | Phase II | Topotecan Berzosertib + Topotecan | Topotecan With or Without M6620 in Treating Patients With Relapsed Small Cell Lung Cancer or Extrapulmonary Small Cell Cancer | Active, not recruiting | USA | 0 |
NCT03898791 | Phase Ib/II | LY3295668 | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer | Completed | USA | TUR | GBR | FRA | ESP | BEL | 2 |
NCT03913455 | Phase II | Carboplatin + Guadecitabine | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | Completed | USA | 0 |
NCT03923270 | Phase I | Durvalumab + Tremelimumab Durvalumab Durvalumab + Olaparib | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03958045 | Phase II | Nivolumab + Rucaparib | Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | Completed | USA | 0 |
NCT03963414 | Phase I | Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Etoposide | A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC | Terminated | USA | 0 |
NCT03964727 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) | Active, not recruiting | USA | FRA | ESP | CAN | BEL | AUS | 2 |
NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT04010357 | Phase II | Abemaciclib | Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC | Recruiting | USA | 0 |
NCT04022876 | Phase I | ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | Terminated | USA | POL | ITA | ESP | DEU | 2 |
NCT04032704 | Phase II | Ladiratuzumab vedotin | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Terminated | USA | ITA | GBR | AUS | 2 |
NCT04047862 | Phase I | BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | Completed | USA | NZL | AUS | 3 |
NCT04101357 | Phase Ib/II | BNT411 Atezolizumab + BNT411 + Carboplatin + Etoposide | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | Terminated | USA | GBR | ESP | DEU | 0 |
NCT04122625 | Phase Ib/II | Nivolumab + Xevinapant | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) | Completed | USA | FRA | ESP | 0 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04165330 | Phase Ib/II | Anlotinib + Nivolumab | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | Active, not recruiting | USA | 0 |
NCT04170946 | Phase I | Talazoparib | Talazoparib and Thoracic RT for ES-SCLC | Recruiting | CAN | 0 |
NCT04173325 | Phase I | Nivolumab Irinotecan + Nivolumab | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | Terminated | USA | 0 |
NCT04209595 | Phase Ib/II | PLX038 + Rucaparib | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | Active, not recruiting | USA | 0 |
NCT04210037 | Phase Ib/II | APG-1252 + Paclitaxel | Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | Terminated | USA | AUS | 0 |
NCT04221529 | Phase II | Atezolizumab | Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide (SPACE) | Active, not recruiting | DEU | AUT | 0 |
NCT04253145 | Phase I | Atezolizumab + Lurbinectedin | Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | Recruiting | ESP | 0 |
NCT04256421 | Phase III | Atezolizumab + Carboplatin + Etoposide + Tiragolumab Atezolizumab + Carboplatin + Etoposide | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02) | Active, not recruiting | USA | TUR | POL | NZL | NLD | ITA | HUN | GRC | GBR | ESP | DEU | CZE | CHE | BRA | BEL | AUT | AUS | 6 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04332653 | Phase Ib/II | NT-I7 + Pembrolizumab | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04334941 | Phase II | Atezolizumab + Talazoparib Atezolizumab | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | Active, not recruiting | USA | 0 |
NCT04350463 | Phase II | CC-90011 + Nivolumab | A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers | Completed | USA | POL | ITA | GBR | FRA | ESP | 0 |
NCT04358237 | Phase Ib/II | Lurbinectedin + Pembrolizumab | Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. (LUPER) | Active, not recruiting | ESP | 0 |
NCT04373369 | Phase II | Atezolizumab + Vorolanib | Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04381650 | Phase Ib/II | Pembrolizumab + Subasumstat | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | POL | LVA | LTU | HRV | CHE | BRA | 2 |
NCT04397003 | Phase II | Carboplatin + Durvalumab + Etoposide Durvalumab + Tremelimumab Durvalumab + Personalized cancer vaccine + Tremelimumab | Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) and Tremelimumab in Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04402788 | Phase II | Atezolizumab Atezolizumab + Radiotherapy | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Recruiting | USA | 0 |
NCT04422210 | Phase I | Atezolizumab + Venetoclax Atezolizumab + Carboplatin + Etoposide + Venetoclax | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). | Terminated | USA | ESP | DNK | 1 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04429087 | Phase I | BI 764532 | A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | Recruiting | USA | ESP | DEU | 1 |
NCT04434482 | Phase I | Senaparib + Temozolomide | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | Completed | USA | AUS | 3 |
NCT04462276 | Phase II | Atezolizumab | Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease (TREASURE) | Active, not recruiting | DEU | AUT | 0 |
NCT04471727 | Phase Ib/II | Atezolizumab + HPN328 HPN328 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | Recruiting | USA | 0 |
NCT04487756 | Phase Ib/II | Atezolizumab + Carboplatin + Etoposide | Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer (VENEZO-LUNG) | Active, not recruiting | ESP | 0 |
NCT04491942 | Phase I | Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Completed | USA | FRA | ESP | CAN | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04514497 | Phase I | Elimusertib + Irinotecan Elimusertib + Topotecan | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04538378 | Phase II | Durvalumab + Olaparib | Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT04543916 | Phase Ib/II | Irinotecan + Venetoclax | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | Withdrawn | 0 | |
NCT04553133 | Phase II | PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 | PF-07104091 as a Single Agent and in Combination Therapy | Active, not recruiting | USA | BGR | ARG | 3 |
NCT04560972 | Phase I | Atezolizumab + Carboplatin + Etoposide + LB-100 Atezolizumab + LB-100 | LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04579757 | Phase Ib/II | Surufatinib + Tislelizumab | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04590781 | Phase Ib/II | Pembrolizumab + XmAb18087 XmAb18087 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
NCT04602533 | Phase II | Cisplatin + Etoposide Durvalumab | Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) | Recruiting | DEU | 0 |
NCT04607954 | Phase II | Durvalumab + Topotecan | Durvalumab and Topotecan for the Treatment of Relapsed or Refractory Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04610658 | Phase Ib/II | Ipilimumab + Lurbinectedin + Nivolumab | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | Terminated | USA | 0 |
NCT04610684 | Phase II | Atezolizumab Atezolizumab + Carboplatin + Etoposide | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | Terminated | USA | 0 |
NCT04624204 | Phase III | Pembrolizumab Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide Olaparib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013) | Active, not recruiting | USA | TUR | ROU | LTU | ITA | ISR | HUN | GRC | GBR | FRA | EST | ESP | CAN | BGR | BEL | AUS | 9 |
NCT04631029 | Phase I | Atezolizumab + Carboplatin + Entinostat + Etoposide Atezolizumab + Entinostat | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | Completed | USA | 0 |
NCT04641871 | Phase I | Sym021 + Sym023 Sym021 + Sym022 | Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies | Completed | USA | FRA | ESP | CAN | 0 |
NCT04696575 | Phase II | Atezolizumab + Carboplatin + Etoposide + Lamivudine Atezolizumab + Lamivudine | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04699838 | Phase II | Carboplatin + Ceralasertib + Durvalumab + Etoposide Ceralasertib + Cisplatin + Durvalumab + Etoposide | Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04701307 | Phase II | Dostarlimab-gxly + Niraparib | Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas | Active, not recruiting | USA | 0 |
NCT04702880 | Phase II | BMS-986012 + Carboplatin + Etoposide + Nivolumab Carboplatin + Etoposide + Nivolumab | A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer | Active, not recruiting | USA | ROU | POL | NLD | ITA | GRC | ESP | CAN | BEL | AUS | 1 |
NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04728230 | Phase Ib/II | Carboplatin + Durvalumab + Etoposide + Olaparib | Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | Recruiting | USA | 0 |
NCT04730999 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Etoposide | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer (CeLEBrATE) | Completed | ITA | 0 |
NCT04745689 | Phase II | AZD2811 + Durvalumab Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN) | Active, not recruiting | USA | POL | ESP | 1 |
NCT04768296 | Phase II | Berzosertib + Topotecan | Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | Completed | USA | ITA | FRA | ESP | BEL | 2 |
NCT04774380 | Phase III | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE) | Active, not recruiting | TUR | ITA | DEU | CZE | CAN | BGR | 0 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Active, not recruiting | USA | 0 |
NCT04802174 | Phase Ib/II | Berzosertib + Lurbinectedin | A Phase I/II Trial of Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers | Recruiting | USA | 0 |
NCT04826341 | Phase Ib/II | Berzosertib + Sacituzumab govitecan-hziy | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | Recruiting | USA | 0 |
NCT04827576 | Phase II | Docetaxel + Hu5F9-G4 | Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC) | Terminated | USA | POL | GBR | FRA | ESP | 0 |
NCT04834778 | Phase I | HC-5404-FU | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | Completed | USA | 0 |
NCT04836195 | Phase I | PCLX-001 | Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Recruiting | CAN | 0 |
NCT04837677 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04870112 | Phase Ib/II | Carboplatin + Cisplatin + Durvalumab + Etoposide Durvalumab | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1) | Terminated | USA | NZL | ESP | 1 |
NCT04885998 | Phase I | AMG 404 + Tarlatamab | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | Completed | USA | BEL | AUT | 3 |
NCT04902040 | Phase Ib/II | Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | Active, not recruiting | USA | 0 |
NCT04919382 | Phase II | Atezolizumab + Temozolomide | Temozolomide and Atezolizumab as Second Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04923776 | Phase II | Atezolizumab + Carboplatin + Etoposide | Liver Directed RT + Chemo-immunotherapy for ES-SCLC | Recruiting | USA | 0 |
NCT04924101 | Phase II | Cisplatin + Etoposide + Lenvatinib + Pembrolizumab Carboplatin + Etoposide + MK-5890 + Pembrolizumab Carboplatin + Etoposide + Lenvatinib + Pembrolizumab Carboplatin + Etoposide + MK-4830 + Pembrolizumab Cisplatin + Etoposide + MK-5890 + Pembrolizumab Cisplatin + Etoposide + MK-4830 + Pembrolizumab | Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | Active, not recruiting | USA | POL | ITA | ISR | HUN | ESP | CHE | CAN | AUT | 2 |
NCT04938817 | Phase Ib/II | Lenvatinib + MK-1308A MK-1308A MK-4280A MK-1308A + MK-4830 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) | Recruiting | USA | POL | ITA | ISR | HUN | ESP | CHE | CAN | AUT | AUS | 2 |
NCT04951115 | Phase II | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer | Completed | USA | 0 |
NCT04952597 | Phase II | Tislelizumab BGBA1217 + Tislelizumab | Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer | Completed | USA | 2 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05027867 | Phase II | KRT-232 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Terminated | USA | HUN | FRA | ESP | DEU | AUS | 1 |
NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05060016 | Phase II | Tarlatamab | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) | Active, not recruiting | USA | POL | NLD | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CHE | BEL | AUT | 5 |
NCT05068232 | Phase II | Carboplatin + Durvalumab + Etoposide Durvalumab | Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) | Recruiting | USA | 0 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05091567 | Phase III | Atezolizumab + Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide + Lurbinectedin | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte) | Active, not recruiting | USA | TUR | POL | ITA | HUN | GRC | GBR | ESP | DEU | BEL | 3 |
NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | 2 | |
NCT05142696 | Phase I | Atezolizumab + Carboplatin + Etoposide + lutetium Lu 177 dotatate Atezolizumab + Carboplatin + Etoposide | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | Recruiting | USA | GBR | FRA | ESP | DEU | 0 |
NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
NCT05161533 | Phase II | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial | Withdrawn | USA | 0 |
NCT05191797 | Phase Ib/II | Atezolizumab + IMG-7289 | Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT05199272 | Phase Ib/II | 23ME-00610 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT05224141 | Phase III | Carboplatin + Etoposide + MK-7684A Cisplatin + Etoposide + MK-7684A Atezolizumab + Cisplatin + Etoposide Atezolizumab + Carboplatin + Etoposide | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008) | Active, not recruiting | USA | TUR | ROU | POL | NLD | LTU | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CAN | AUT | AUS | ARG | 5 |
NCT05263180 | Phase I | EMB-09 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Recruiting | AUS | 1 |
NCT05268666 | Phase Ib/II | JBI-802 | A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05271292 | Phase Ib/II | Chiauranib | Chiauranib for Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Recruiting | USA | 0 |
NCT05280470 | Phase II | Ifinatamab deruxtecan | DS-7300a in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Active, not recruiting | USA | FRA | ESP | DEU | 4 |
NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Suspended | USA | 0 |
NCT05353257 | Phase III | Cisplatin + Etoposide + Serplulimab Carboplatin + Etoposide + Serplulimab | A Study to Evaluate the Efficacy and Safety of HLX10 in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer | Recruiting | USA | POL | NLD | LVA | HUN | GRC | ESP | DEU | CZE | AUT | 1 |
NCT05353439 | Phase I | Pembrolizumab + Tazemetostat + Topotecan | Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | Suspended | USA | 0 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05361395 | Phase I | Atezolizumab + Tarlatamab Atezolizumab + Carboplatin + Etoposide + Tarlatamab | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Active, not recruiting | USA | NLD | ITA | ISR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUS | 3 |
NCT05363280 | Phase II | AL8326 | AL8326 in SCLC Treatment | Recruiting | USA | 0 |
NCT05384015 | Phase II | Carboplatin + Etoposide + Lenvatinib + Pembrolizumab | Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (PEERS) | Recruiting | ESP | 0 |
NCT05394103 | Phase Ib/II | Q901 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05403723 | Phase I | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC | Suspended | USA | 0 |
NCT05420636 | Phase II | ORY-1001 + Paclitaxel | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET | Recruiting | USA | 0 |
NCT05438329 | Phase Ib/II | DB-1305 | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT05450965 | Phase II | Onvansertib | Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05468489 | Phase III | Atezolizumab + Carboplatin + Etoposide Carboplatin + Etoposide + Serplulimab | To Evaluate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC | Recruiting | USA | 0 |
NCT05505825 | Phase Ib/II | Cadonilimab + Chiauranib | A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | Active, not recruiting | AUS | 1 |
NCT05546268 | Phase Ib/II | MRT-2359 | Study of Oral MRT-2359 in Selected Cancer Patients | Recruiting | USA | CAN | 0 |
NCT05557708 | Phase I | 212Pb-Pentixather | A Safety Study of 212Pb-Pentixather Radioligand Therapy | Not yet recruiting | USA | 0 |
NCT05566041 | Phase III | Cisplatin + Etoposide Carboplatin + Etoposide + RRx-001 Cisplatin + Etoposide + RRx-001 Carboplatin + Etoposide | A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer (REPLATINUM) | Active, not recruiting | USA | 0 |
NCT05572476 | Phase II | Durvalumab + Lurbinectedin Carboplatin + Etoposide | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer (LURBIMUNE) | Withdrawn | FRA | 0 |
NCT05578326 | Phase II | Lurbinectedin + Trilaciclib | Study of Trilaciclib and Lurbinectidin | Recruiting | USA | 0 |
NCT05588388 | Phase II | Bevacizumab | Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases (BELIEVE) | Recruiting | USA | 0 |
NCT05595460 | Phase I | Atezolizumab + Carboplatin + Etoposide + RYZ101 | Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC | Recruiting | USA | 1 |
NCT05599984 | Phase I | ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | Recruiting | USA | ITA | ISR | FRA | ESP | DEU | AUS | 2 |
NCT05617963 | Phase II | Durvalumab | Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax (DURVALUNG) | Recruiting | FRA | 0 |
NCT05619744 | Phase I | RO7616789 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | Recruiting | USA | POL | ESP | DNK | 1 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05620342 | Phase I | iC9.GD2.CAR.IL-15 T-cells | Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | Recruiting | USA | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05623319 | Phase II | Cisplatin + Etoposide + Pembrolizumab Olaparib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) (THOR) | Recruiting | ITA | 0 |
NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05652686 | Phase I | PT217 | A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | Recruiting | USA | 0 |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05655598 | Phase I | Palbociclib + Pimitespib | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Withdrawn | USA | 0 |
NCT05680922 | Phase I | LB2102 | DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05691491 | Phase Ib/II | M1774 + Temozolomide | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | Recruiting | USA | 0 |
NCT05700721 | Phase II | Dostarlimab-gxly + Niraparib | Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) | Recruiting | USA | 0 |
NCT05703971 | Phase Ib/II | Atezolizumab + Quaratusugene Ozeplasmid | Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3) | Recruiting | USA | 0 |
NCT05703997 | Phase II | Atezolizumab | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction (FASTIMMUNE) | Not yet recruiting | ITA | 0 |
NCT05718323 | Phase II | Niraparib | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (RAISE) | Recruiting | ROU | ITA | FRA | ESP | CHE | 0 |
NCT05740566 | Phase III | Lurbinectedin Topotecan Amrubicin Tarlatamab | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT05796089 | Phase II | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy (CHEST RT) | Recruiting | AUS | 0 |
NCT05815160 | Phase I | Carboplatin + Debio 0123 + Etoposide | Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy | Recruiting | USA | ESP | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05856695 | Phase II | Carboplatin + Durvalumab + Paclitaxel | A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) (TAXIO) | Recruiting | FRA | 0 |
NCT05874401 | FDA approved | Topotecan + Trilaciclib Topotecan | Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | Recruiting | TUR | POL | HUN | GRC | ESP | DEU | BGR | BEL | AUT | 1 |
NCT05879978 | Phase Ib/II | BI 764532 + Ezabenlimab | A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | Recruiting | FRA | DEU | BEL | 1 |
NCT05882058 | Phase II | BI 764532 | DAREO-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | BEL | 5 |
NCT05886868 | Phase I | BL0020 | Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors | Recruiting | AUS | 1 |
NCT05903092 | Phase II | Carboplatin + Durvalumab + Etoposide + Monalizumab Cisplatin + Durvalumab + Etoposide + Monalizumab | MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART) | Recruiting | USA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT05914116 | Phase Ib/II | DB-1311 | A Study of DB-1311 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05963867 | Phase I | BI 764532 | A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer | Recruiting | NLD | 0 |
NCT05990738 | Phase I | BI 764532 + Topotecan | DAREON-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan | Recruiting | USA | POL | GBR | FRA | DEU | 0 |
NCT06016270 | Phase Ib/II | hSTC810 + Paclitaxel | A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 1 |
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
NCT06077500 | Phase I | BI 764532 + Cisplatin + Durvalumab + Etoposide BI 764532 + Carboplatin + Durvalumab + Etoposide Atezolizumab + BI 764532 + Carboplatin + Etoposide | DAREON-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (DAREON-8) | Recruiting | USA | POL | FRA | ESP | DEU | CHE | BEL | 0 |
NCT06095505 | Phase II | Alisertib | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06095583 | Phase III | Icatolimab + Toripalimab-tpzi Toripalimab-tpzi | Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | FRA | ESP | DEU | BEL | 4 |
NCT06110572 | Phase Ib/II | Atezolizumab + Carboplatin + Etoposide | Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TESSERACT) | Recruiting | USA | 0 |
NCT06117774 | Phase III | Tarlatamab | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (DeLLphi-306) | Recruiting | USA | TUR | GRC | DEU | CHE | BRA | BEL | AUS | ARG | 6 |
NCT06131840 | Phase I | SGN-CEACAM5C | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Recruiting | USA | SWE | NLD | GBR | ESP | CAN | 0 |
NCT06140407 | Phase II | Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06179069 | Phase I | ZL-1310 | An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer | Recruiting | USA | 1 |
NCT06203210 | Phase III | Ifinatamab deruxtecan Amrubicin Lurbinectedin Topotecan | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 5 |
NCT06211036 | Phase III | Durvalumab + Tarlatamab Durvalumab | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305) | Recruiting | USA | TUR | CHE | BRA | AUS | ARG | 5 |
NCT06223711 | Phase II | Durvalumab Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC | Recruiting | DEU | 0 |
NCT06227546 | Phase II | MGC018 | A Phase II Study of MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (MGC018-SCLC) | Recruiting | USA | 0 |
NCT06240728 | Phase I | NPX887 | A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7 | Recruiting | USA | 0 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT06257264 | Phase I | BG-68501 + Fulvestrant BG-68501 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | Recruiting | USA | AUS | 1 |
NCT06264921 | Phase I | NKT3447 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06362252 | Phase Ib/II | Atezolizumab + Carboplatin + Ifinatamab deruxtecan Atezolizumab + Carboplatin + Etoposide Atezolizumab + Ifinatamab deruxtecan | A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | Recruiting | USA | FRA | ESP | 1 |
NCT06449209 | Phase II | BNT327 | Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy | Recruiting | USA | GBR | AUS | 1 |
NCT06479811 | Phase I | 212Pb-VMT-alpha-NET | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | Not yet recruiting | USA | 0 |
NCT06480240 | Phase Ib/II | OBI-992 | A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06577987 | Phase I | CID-078 | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT06586957 | Phase I | NKT3964 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06598306 | Phase I | Tarlatamab | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (DeLLphi-308) | Recruiting | USA | AUS | 1 |
NCT06613009 | Phase I | IBI3009 | Study of IBI3009 in Subjects With Unresectable, Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | Not yet recruiting | AUS | 0 |
NCT06663098 | Phase II | Atezolizumab + Carboplatin + Etoposide | Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). (CARRY-ON) | Not yet recruiting | ITA | 0 |
NCT06681220 | Phase II | Lurbinectedin Niraparib + Temozolomide | Biomarker Directed Trial of Temozolomide and PARP Inhibition in Relapsed SCLC (Relapsed SCLC) | Not yet recruiting | USA | 0 |